Market data loadingS&P 500--NASDAQ--Data as of latest ETNo timestamp

Tilray Brands, Inc. (TLRY) Guidance & Earnings Results

On 2026-10-08 Tilray Brands, Inc. reaffirmed guidance: "FY2027 adjusted EBITDA…" — from its own filing, as read by EquiReason.

Source: SEC EDGAR filings · figures as of 2026-08-31 · read by EquiReason

TLRYTilray Brands, Inc.Follow TLRY — free
Drug Manufacturers - Specialty & Generic · Healthcare
—
Price chart with a free account
Market cap
415.3M
P/E TTM
—
Dividend yield
—
52-week
—
Next earnings
6 Jan, in 74 days

What management guided

each earnings 8-K · figures checked against the filing text
ReleaseDirectionWhat they said
8 Oct 26ReaffirmedFY2027 adjusted EBITDA $68-75M · full year
28 Jul 26RaisedFY2027 adjusted EBITDA guidance $68-75M, reflecting double-digit growth; expects over $1B annual revenue · full year
1 Apr 26ReaffirmedFY2026 adjusted EBITDA guidance reconfirmed; no specific numbers provided in excerpt. · full year
8 Jan 26ReaffirmedFY2026 adjusted EBITDA $62-72 million · full year
9 Oct 25ReaffirmedFY26 adjusted EBITDA $62-72M · full year
28 Jul 25RaisedFY2026 Adjusted EBITDA $62M-$72M · full year

Tilray Brands, Inc. — questions

What guidance did Tilray Brands, Inc. give?
On 2026-10-08: "FY2027 adjusted EBITDA $68-75M"
When does Tilray Brands, Inc. report earnings?
Tilray Brands, Inc.'s next earnings report is expected on 2027-01-06.

Every figure on this page comes from Tilray Brands, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.